Revlimid was already on pace to deliver sales of more than $5 billion this year as the leading second-line treatment for the indication; the FDA and EU's approval for its use in newly diagnosed patients could mean that sales finish 2015 closer to an annualized $6 billion pace than a $5 billion pace. Celgene should also be able to notch solid sales growth from its third-line multiple myeloma drug Pomalyst and its cancer drug Abraxane.